CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Price, Quote, News and Overview
NASDAQ:CTNM - Nasdaq - US21217B1008 - Common Stock - Currency: USD
CTNM Quote, Performance and Key Statistics
NASDAQ:CTNM (5/2/2025, 8:00:01 PM)
4.1
+0.13 (+3.27%)
The current stock price of CTNM is 4.1 USD. In the past month the price decreased by -33.12%. In the past year, price decreased by -70.9%.
CTNM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
| JNJ | JOHNSON & JOHNSON | 15.53 | 376.23B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.01 | 307.32B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
| PFE | PFIZER INC | 7.54 | 137.25B | ||
| SNY | SANOFI-ADR | 14.36 | 135.72B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
| GSK | GSK PLC-SPON ADR | 7.09 | 79.05B | ||
| ZTS | ZOETIS INC | 26.59 | 70.23B | ||
| HLN | HALEON PLC-ADR | 21.84 | 48.28B |
Related stock screener links
About CTNM
Company Profile
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Company Info
CONTINEUM THERAPEUTICS INC-A
3565 General Atomics Court, Suite 200
San Diego CALIFORNIA US
Employees: 41
Company Website: https://www.contineum-tx.com/
Investor Relations: http://www.contineum-tx.com/investors/
Phone: 18583335280
CONTINEUM THERAPEUTICS INC-A / CTNM FAQ
What is the stock price of CONTINEUM THERAPEUTICS INC-A today?
The current stock price of CTNM is 4.1 USD. The price increased by 3.27% in the last trading session.
What is the ticker symbol for CONTINEUM THERAPEUTICS INC-A stock?
The exchange symbol of CONTINEUM THERAPEUTICS INC-A is CTNM and it is listed on the Nasdaq exchange.
On which exchange is CTNM stock listed?
CTNM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CONTINEUM THERAPEUTICS INC-A stock?
11 analysts have analysed CTNM and the average price target is 25.3 USD. This implies a price increase of 516.98% is expected in the next year compared to the current price of 4.1. Check the CONTINEUM THERAPEUTICS INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CONTINEUM THERAPEUTICS INC-A worth?
CONTINEUM THERAPEUTICS INC-A (CTNM) has a market capitalization of 106.07M USD. This makes CTNM a Micro Cap stock.
How many employees does CONTINEUM THERAPEUTICS INC-A have?
CONTINEUM THERAPEUTICS INC-A (CTNM) currently has 41 employees.
What are the support and resistance levels for CONTINEUM THERAPEUTICS INC-A (CTNM) stock?
CONTINEUM THERAPEUTICS INC-A (CTNM) has a support level at 4 and a resistance level at 4.35. Check the full technical report for a detailed analysis of CTNM support and resistance levels.
Should I buy CONTINEUM THERAPEUTICS INC-A (CTNM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTNM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTNM, evaluating the profitability, health, valuation and growth aspects
- CONTINEUM THERAPEUTICS INC-A (CTNM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Sales and EPS estimates to see what analysts future expectations are.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Chart to make your own analysis
- CONTINEUM THERAPEUTICS INC-A (CTNM) Latest news and press-releases to stay up to date.
Does CONTINEUM THERAPEUTICS INC-A (CTNM) stock pay dividends?
CTNM does not pay a dividend.
When does CONTINEUM THERAPEUTICS INC-A (CTNM) report earnings?
CONTINEUM THERAPEUTICS INC-A (CTNM) will report earnings on 2025-05-15.
What is the Price/Earnings (PE) ratio of CONTINEUM THERAPEUTICS INC-A (CTNM)?
CONTINEUM THERAPEUTICS INC-A (CTNM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.9).
What is the Short Interest ratio of CONTINEUM THERAPEUTICS INC-A (CTNM) stock?
The outstanding short interest for CONTINEUM THERAPEUTICS INC-A (CTNM) is 4.21% of its float. Check the ownership tab for more information on the CTNM short interest.
CTNM Technical Analysis
CTNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTNM. CTNM has a great financial health rating, but its profitability evaluates not so good.
CTNM Financial Highlights
Over the last trailing twelve months CTNM reported a non-GAAP Earnings per Share(EPS) of -4.9. The EPS decreased by -341.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.85% | ||
| ROE | -21.34% | ||
| Debt/Equity | 0 |
CTNM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to CTNM. The Buy consensus is the average rating of analysts ratings from 11 analysts.